





51

Test Results









53

Frame structural performance – Over Expansion









54

Crimp profile evaluations - Latest Iterations







Crimp profile evaluations - Current status



Possible improvements:









58

S3 Valve Build plan for 2010 - 2011












60

Verification & Validation Main Tasks




Animal Study GLP Study- Plan










SAPIEN 3 - Model 9500TFX Final Packaging





Regulatory Strategy - Assumptions





Regulatory Strategy - Overview



Regulatory Review Periods



^{*} Based on historical product registration approval timeframes





Risk management plan


- RMP HVOO7
- The Risk Management Plan covers only the valve design control stage.








Main Design FMEA Risks






Main System Risks





Main Project Risks





Document Checklist for CDR:

In compliance to SOP



Documents Pending signature









THV3 26mm Frames Manufacturing Material Flow







Detailed Frame Manufacturing Current Flow Chart










Animal Trial -



Incidence and Predictors of Permanent Pacemaker Requirement after Transcatheter Aortic Valve Implantation with a Self-Expanding Bioprosthesis

NUNO DIAS FERREIRA, M.D., DANIEL CAEIRO, M.D., LUÍS ADÃO, M.D., MARCO OLIVEIRA, M.D., HELENA GONÇALVES, M.D., JOSÉ RIBEIRO, M.D., MADALENA TEIXEIRA, M.D., ANÍBAL ALBUQUERQUE, M.D., JOÃO PRIMO, M.D., PEDRO BRAGA, M.D., LINO SIMÕES, M.D., and VASCO GAMA RIBEIRO, M.D. From the Department of Cardiology, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal



Requirement for PPM was significantly correlated with prosthesis depth in the LVOT (P = 0.001; r = 0.590). Mean distance from the annular margin of the noncoronary cusp to the ventricular end of the prosthesis was significantly greater in patients with PPM requirement than patients without PPM requirement (12.9 \pm 2.5 mm vs 8.6 \pm 2.9, respectively). At a cutoff point of 10.1 mm, the likelihood of PPM implantation could be predicted with 87.5% sensitivity and 74% specificity and a receiver operator characteristic curve area of 0.86 \pm 0.07 (P = 0.003).

EDWARDS TRANSCATHETER HEART VALVE PROGRAM

SAPIEN 3 Valve development team







